Financials NurExone Biologic Inc. Deutsche Boerse AG
Equities
J90
CA67059R1091
Biotechnology & Medical Research
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.469 EUR | +4.22% |
|
-4.74% | +158.48% |
05-29 | NurExone Biologic Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
04-25 | NurExone Biologic Announces OTCQB Listing And DTC Eligibility | MT |
Valuation
Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|
Capitalization 1 | 12.25 | 10.75 | 35.48 | - | - |
Enterprise Value (EV) 1 | 12.25 | 10.75 | 35.48 | 35.48 | 35.48 |
P/E ratio | -1.32 x | -2.75 x | -6.6 x | -6.6 x | -10.6 x |
Yield | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - |
EV / Revenue | - | - | - | - | - |
EV / EBITDA | - | - | - | - | - |
EV / FCF | - | - | - | - | - |
FCF Yield | - | - | - | - | - |
Price to Book | - | - | - | - | - |
Nbr of stocks (in thousands) | 42,855 | 48,250 | 67,162 | - | - |
Reference price 2 | 0.2858 | 0.2228 | 0.5283 | 0.5283 | 0.5283 |
Announcement Date | 23-03-30 | 24-04-02 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - |
EBITDA | - | - | - | - | - |
EBIT 1 | - | -3.657 | -4.62 | -4.75 | - |
Operating Margin | - | - | - | - | - |
Earnings before Tax (EBT) 1 | - | -3.639 | -4.669 | -4.737 | - |
Net income 1 | -8.169 | -3.639 | -4.669 | -4.737 | - |
Net margin | - | - | - | - | - |
EPS 2 | -0.2160 | -0.0810 | -0.0800 | -0.0800 | -0.0500 |
Free Cash Flow | - | - | - | - | - |
FCF margin | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - |
Dividend per Share | - | - | - | - | - |
Announcement Date | 23-03-30 | 24-04-02 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - | - | - |
EBIT 1 | -1.06 | -1.164 | -0.716 | -0.92 | -1.1 | -1.2 | -1.4 | -1.05 | -1.1 |
Operating Margin | - | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -1.04 | -1.158 | -0.737 | -0.922 | -1.101 | -1.201 | -1.401 | -1.035 | -1.101 |
Net income 1 | -1.04 | -1.158 | -0.737 | -0.922 | -1.101 | -1.201 | -1.401 | -1.035 | -1.101 |
Net margin | - | - | - | - | - | - | - | - | - |
EPS 2 | -0.0240 | -0.0260 | -0.0150 | -0.0160 | -0.0200 | -0.0200 | -0.0200 | -0.0200 | -0.0200 |
Dividend per Share | - | - | - | - | - | - | - | - | - |
Announcement Date | 23-08-28 | 23-11-24 | 24-04-02 | 24-05-29 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|
Net Debt | - | - | - | - |
Net Cash position | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - |
Free Cash Flow | - | - | - | - |
ROE (net income / shareholders' equity) | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - |
Assets 1 | - | - | - | - |
Book Value Per Share | - | - | - | - |
Cash Flow per Share | - | - | - | - |
Capex | - | - | - | - |
Capex / Sales | - | - | - | - |
Announcement Date | 23-03-30 | 24-04-02 | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+16.59% | 44.44B | |
+41.02% | 39.84B | |
-10.62% | 37.68B | |
+29.92% | 31.46B | |
-9.23% | 27.02B | |
+12.34% | 26.29B | |
+41.53% | 13.8B | |
+31.49% | 12.46B | |
-7.40% | 11.26B |
- Stock Market
- Equities
- NRX Stock
- J90 Stock
- Financials NurExone Biologic Inc.